New-onset heart failure

1. Tirzepatide is linked with lower new-onset heart failure in humans (compared with semaglutide in a new-user active-comparator cohort) (1.04% vs 1.29%; HR 0.79 (95% CI 0.68-0.92)).

   “driven by reduced new-onset HF (1.04% vs. 1.29%; HR, 0.79; 95% CI, 0.68-0.92; p = 0.002)”

   Humanscompared with semaglutide in a new-user active-comparator cohort12 monthsn = 35,336

   Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults

   Diabetes, obesity & metabolism·Mar 27, 2026

More on Tirzepatide

1. Positive PRESENT-SHD ensemble screen predicts new-onset heart failure in humans (Patients without prior heart failure at MGH; adjusted analysis) (aHR 3.40 [3.22-3.59]).

   “The ensemble SHD model conferred 3.4-fold risk (aHR 3.40 [3.22-3.59]) at MGH”

   HumansPatients without prior heart failure at MGH; adjusted analysisMedian 3.6 yearsn = 178,537

   AI heart-tracing screens linked to later heart failure

   AHA Scientific Sessions 2026 abstract·Nov 2, 2026

More on Positive PRESENT-SHD ensemble screen

1. GLP-1 receptor agonists are associated with new-onset heart failure in humans (Prior myocardial infarction and overweight or obesity; compared with SGLT2 inhibitors) (HR 0.58, 95% CI 0.53 to 0.63; 8.9% vs 15.4%).

   “GLP-1 RA use was associated with substantially lower risk of MACE and new-onset heart failure than SGLT2i”

   HumansPrior myocardial infarction and overweight or obesity; compared with SGLT2 inhibitorsMedian follow-up about 1.5 years61% males

   Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Prior Myocardial Infarction and Overweight or Obesity: A Propensity-Matched Analysis

   AHA Scientific Sessions 2026 abstract·Nov 2, 2026

More on GLP-1 receptor agonists

1. Body mass index is associated with new-onset heart failure in humans (BMI ≥40 in patients undergoing first-time catheter ablation for atrial fibrillation) (BMI ≥40: HR 2.31, 95% CI 1.56–3.41).

   “Elevated BMI is independently associated with new-onset HF after AF ablation, with risk rising progressively across BMI categories.”

   HumansBMI ≥40 in patients undergoing first-time catheter ablation for atrial fibrillation3.6±2.9 years of follow-upn = 7,363

   Association between Elevated Body Mass Index and New-Onset Heart Failure in Patients Undergoing Catheter Ablation for Atrial Fibrillation

   Frontiers in cardiovascular medicine·Nov 2, 2026

1. Vascular Cytokines RTS predicts new-onset heart failure in humans (Highest Vascular Cytokines RTS quartile) (1.6-times higher risk; p<0.001).

   “Similar positive associations were observed for new onset heart failure and chronic kidney disease”

   HumansHighest Vascular Cytokines RTS quartile

   Artery inflammation score linked to higher cardiac death risk

   ESC Congress 2026 abstract·Oct 26, 2026

More on Vascular Cytokines RTS

1. Finerenone is associated with new-onset heart failure in humans (6.5 vs 12.9 events/100 person-years; incidence rate difference -6.38 (95% CI -9.75 to -3.02)).

   “and new-onset HF (6.5 vs 12.9; -6.38; 95% CI, -9.75 to -3.02)”

   HumansType 2 diabetes and chronic kidney disease without prior heart failure or ischemic heart disease; prior first-line SGLT2 inhibitor therapy; compared with steroidal MRAs18 months

   Finerenone versus Steroidal MRAs in Type 2 Diabetes and Chronic Kidney Disease without Prior Heart Failure

   ESC heart failure·Oct 19, 2026

More on Finerenone

1. Tirzepatide is linked with a lower risk of new-onset heart failure in humans (compared with semaglutide in patients with obesity) (HR 0.9; absolute risk difference −0.3%).

   “The incidence of new-onset HF was lower in the tirzepatide group (1.0% vs. 1.3%; absolute risk difference −0.3%, 95% CI −0.35 to −0.26; HR 0.9, 95% CI 0.86─0.93).”

   Humanscompared with semaglutide in patients with obesityone yearn = 424,269

   New-Onset Heart Failure in Patients with Obesity using Tirzepatide or Semaglutide

   medRxiv·Sep 26, 2026Preprint

More on Tirzepatide

1. PCSK9 inhibitors are linked with a lower risk of new-onset heart failure in humans (propensity-matched patients with dyslipidemia, compared with statin users) (HR 0.69, 95% CI 0.63-0.76; 1.8 vs. 2.7 per 100 person-years).

   “The incidence of new-onset HF was significantly lower in the PCSK9is group (1.8 vs. 2.7 per 100 person-years; HR 0.69, 95% CI 0.63-0.76; P < .001)”

   Humanspropensity-matched patients with dyslipidemia, compared with statin users1 yearn = 40,098

   Association Between PCSK9 Inhibitor Use and Risk of Incident Heart Failure in Patients With Dyslipidemia

   QJM : monthly journal of the Association of Physicians·Sep 10, 2026

More on PCSK9 inhibitors